Review

Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome

Ponti G., Castellsagué E., Ruini C., Percesepe A., Tomasi A. Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome. *Clin Genet* 2015; 87: 507–516. © John Wiley & Sons A/S. Published by John Wiley & Sons Ltd, 2014

Founder mutations in specific populations are common in several Mendelian disorders. They are shared by apparently unrelated families that inherited them from a common ancestor that existed hundreds to thousands of years ago. They have been proven to impact in molecular diagnostics strategies in specific populations, where they can be assessed as the first screening step and, if positive, avoid further expensive gene scanning. In Lynch syndrome (LS), a dominantly inherited colorectal cancer disease, more than 50 founder pathogenic mutations have been described so far in the mismatch repair (MMR) genes (*MLH1*, *MSH2*, *MSH6* and *PMS2*). We here provide a comprehensive summary of the founder mutations found in the MMR genes and an overview of their main characteristics. At a time when high-throughput strategies are being introduced in the molecular diagnostics of cancer, genetic testing for founder mutations can complement next generation sequencing (NGS) technologies to most efficiently identify MMR gene mutations in any given population. Additionally, special attention is paid to MMR founder mutations with interesting anthropological significance.

Conflict of interest

The authors have declared no conflicting interests.

G. Ponti^a, E. Castellsagué^{b,c}, C. Ruini^d, A. Percesepe^e and A. Tomasi^a

^aDepartment of Diagnostic and Clinical Medicine and Public Health, University of Modena and Reggio Emilia, Modena, Italy, ^bDepartment of Human Genetics, McGill University, Montreal, Canada, ^cTranslational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, Barcelona, Spain, ^dDepartment of Dermatology, and ^eDepartment of Genetics, University of Modena and Reggio Emilia, Modena, Italy

Key words: founder mutation – genetic anticipation phenomenon – HNPCC – Lynch syndrome – *MLH1* – MMR – *MSH2* – *MSH6* – Muir-Torre syndrome – *PMS2*

Corresponding author: Dr Giovanni Ponti, MD, PhD, Department of Diagnostic and Clinical Medicine and Public Health; University of Modena and Reggio Emilia, Via del Pozzo 71, 41124 Modena, Italy.
Tel.: +39594224748;
fax: +39594224271;
e-mail: giovanni.ponti@unimore.it

Received 25 August 2014, revised and accepted for publication 17 October 2014

The year 2013 marked the hundredth anniversary of the first description of the cancer predisposing syndrome initially known as cancer family syndrome, then hereditary non-polyposis colorectal cancer (HNPCC), and finally Lynch Syndrome (LS) (1, 2). LS is the most common cause of hereditary colorectal cancer (CRC), showing an autosomal dominant inheritance pattern. In addition to CRC, LS is characterized by an increased risk of malignancies at certain extracolonic sites such as the endometrium, ovary, stomach and small bowel, among others (3). LS is caused by germline mutations in one of the DNA mismatch repair (MMR) genes (*MLH1*, *MSH2*, *MSH6*, and *PMS2*) (4–7). Constitutional epimutations,

characterized by soma-wide allele specific promoter methylation and transcriptional silencing of *MLH1* and *MSH2* (in the latter gene the transcriptional inactivation is secondary to deletions in the neighboring *EPCAM* gene), also trigger LS (8). Therefore, MMR deficiency is the characteristic signature of LS tumors, and provides us with two useful identification tools: microsatellite instability (MSI) and loss of immunohistochemical (IHC) staining of the MMR proteins (9). Systematic tumor testing by MSI or IHC for all patients with CRC (or CRC <70 years) and all patients with endometrial cancer (EC) (or EC <70 years) has been recommended for the identification of patients with LS (10).

As a result of ~20 years of mutation analysis worldwide, more than 1000 unique DNA variants have been reported for each of the two major LS genes, *MLH1* and *MSH2*, plus several hundred for *MSH6* and *PMS2* (11). When the individuals carrying the mutations are considered, the numbers are up to six times higher (11), implying that mutations tend to recur among the populations. Two situations cause this recurrence of mutations among unrelated families. On the one hand, in the so-called recurrent mutations, sequence peculiarities can predispose to an abnormal event at meiosis making a mutation to arise repeatedly *de novo* (e.g. c.942+3A>T in *MSH2*) (12, 13). On the other hand, the so-called founder mutations arose in a single ancestor who subsequently passed it on to succeeding generations. In order to prove that a particular mutation is a founder, it is necessary to haplotype several markers [single nucleotide polymorphisms (SNPs) or microsatellites] surrounding the mutation in both carriers and non-carriers. If all carrier individuals from the different families share a common haplotype not frequently present in non-carriers, we can conclude that most probably the mutation originated in a single founder individual who spread the mutation. We expect that the shorter the haplotype is, the older is the mutation. By means of haplotyping cases and controls, we are also able to estimate the age of founder mutations using one of the several mathematical models described (14–21). It is founder mutations that are the subject of this review.

Two alternative founder mutation-enrichment mechanisms are believed to take place. Some founder mutations could be positively selected through natural selection because they carry an advantage (22). In other cases, in isolated populations without significant genetic influx, a new mutation can be enriched by genetic drift. In such cases, the mutation could have appeared *de novo* or could have come with the new founder individuals (founder effect). Because genetic drift is enhanced in small populations we find numerous examples of founder mutations in relatively isolated regions (e.g. Quebec, Newfoundland, Tenerife Island in Spain), countries (e.g. Finland, Iceland, Netherlands) or ethnic groups such as the Ashkenazi Jews (AJ). The tradition of intermarriage among members of the same community during the last millennium has led the AJ to a genetic isolation. Their unusual high prevalence of disease-associated mutations is consistent with the occurrence of several founding events, repeated bottlenecks and dramatic expansions among their history (23). Founder mutations have been also discovered in large, genetically heterogeneous populations (e.g. Europe, North-America).

Founder mutations can cause recessive patterns of pathogenicity such as hemochromatosis (24), beta thalassemia (25), cystic fibrosis (26) or xeroderma pigmentosum (27) among others. In dominant predisposing diseases, founder mutations usually exist when the age of onset of the disease is past the reproductive age, so they are not eliminated because of reduced reproductive fitness. This is the case of some cancer-predisposing founder mutations that have been found, among others, in *BRCA1* and *BRCA2* genes causing hereditary breast and ovarian cancer syndrome (28), in *CDKN2A* gene

causing cutaneous malignant melanoma (29), or in the MMR genes causing LS (30). In the latter case, more than 50 founder mutations have been identified so far. In this review, we aim to summarize all the published founder mutations causing LS, paying special attention to those with clinical or anthropological relevance.

MMR genes founder mutations in LS

Founder mutations in specific regions

At least 55 founder mutations causing LS have been described so far (Tables 1–3). Although some mutations have been seen in only a couple of unrelated families, their single origin is supported by haplotype analysis in cases and controls. In other cases, founder mutations result to be very commonly found in specific countries or areas, representing a very useful tool in regional genetic screening of LS.

The most evident example of this, is probably the case of the two *MLH1* Finnish founder mutations (c.454-1G>A and exon 16 deletion) that together, account for ~50% of LS families in Finland (31, 32). In 1996, Moisio and colleagues performed genealogical and haplotype analyses in families carrying these two mutations, and not only were the first to describe the existence of founder mutation in LS, but also were able to estimate their age. Numerous other founders existing in a relatively high proportion of LS families in particular areas have been described. In Spain, c.306+5G>A and c.1865T>A *MLH1* mutations represent the 17.6% of MMR mutations in a specific series of families residing in Catalonia (33). Around 25% of Danish families that fulfill Amsterdam criteria are carriers of a founder splicing mutation (c.1667+2_1667+8del7ins4) in *MLH1* gene (34, 35). Twenty percent of the LS families identified in a series of Hong Kong, carry the novel c.1452_1455del *MSH2* mutation (36). In Portugal, Pinheiro et al. described two founder mutations that have been proved to be very prevalent: a large deletion comprising exons 17–19 of the *MLH1* gene and exons 26–29 of the contiguous *LRRFIP2* gene, and the c.388_389del in *MSH2* gene, represent 17% and 16% of LS-causing mutation in their series, respectively (37, 38). Interestingly, the c.388_389del in *MSH2* gene appeared independently in families from Germany, Scotland, England and Argentina, who did not share the Portuguese haplotype, which led authors to the conclusion that it may be a mutational hotspot within the *MSH2* gene, probably due to the existence of a short repeat motif (TCTCTCTC) existing upstream of the deletion (37). Similarly, in the province of Newfoundland (Canada) the c.942+3A>T *MSH2* mutation was found in 11 families. Although this mutation is the most common recurrent mutation in MMR genes, repeatedly arising *de novo* because of misalignment at replication or recombination caused by the presence of 26 adenines (13, 39). Newfoundland carriers share a common ancestral haplotype not present in carriers from England, Italy, Hong Kong or Japan (12, 39). Therefore, this recurrent mutation also appeared with a founder

Mismatch repair genes founder mutations in Lynch syndrome

Table 1. Founder mutations in *MLH1* gene

Mutation	Region/ population	Estimated age (years) ^a	Families ^b	Haplotype	Features	Ref.
c.[−27C>A; c.85G>T] (p.Ala29Ser)	Caucasians	–	5	Yes	Epigenetic silencing of MLH1	(67)
c.112A>C (p.Asn38His)	Netherlands	–	6	Yes	–	(84)
c.306+5G>A	Spain	~1879	17	Yes	Moderate penetrance	(33)
c.392C>T (p.Ser131X)	Republic of Macedonia	–	3	Yes	–	(85)
c.454-1G>A	Finland	125–525	5	Yes	Highly frequent among Finnish LS patients	(31, 32)
c.545+3A>G	Italy	–	1	Yes	–	(70)
	Quebec (Italian ancestors)	–	1	Yes	–	(70)
	Brazil	–	3	No	–	(72, 73)
c.589-2A>G	US	~450	10	Yes	1% of US LS families	(61)
	Italy	–	3	Yes	–	(61)
c.731G>A (p.Gly244Asp)	Italy	–	3	Yes	–	(86)
c.793C>T (p.Arg265Cys)	Taiwan	–	13	Yes	20% of Amsterdam families	(87)
c.1381A>T (p.Lys461X)	North America	–	3	Yes	–	(88)
c.1489dup (p.Arg497fs)	Germany	–	21	No	–	(89)
c.1558+1G>T (p.Val520fs)	Italy	–	2	Yes	–	(86)
c.1667+2_1667+8del7ins4	Denmark	–	16	Yes	~25% of Amsterdam families	(34, 35)
c.1731G>A (p.=)	Italy	–	2	Yes	Low risk for extracolonic tumors	(86)
c.1758dup (p.Met587fs)	Korea	–	11	Yes	–	(90)
c.1831delAT (p.Ile611fs)	Quebec (Italian ancestors)	–	2	Yes	–	(70)
c.1865T>A (p.Leu622His)	Spain	–	12	Yes	Moderate penetrance	(33)
c.2142G>A (p.Trp714X)	Swiss	>200	1	Yes	–	(91)
c.2195_2198dup (p.His733fs)	Quebec	–	5	Yes	–	(92)
c.2252_2253del (p.Lys751fs)	Italy	~1550	11	Yes	Increased risk of pancreatic tumors	(82)
c.2269dup	Italy	–	4	Yes	–	(74)
(p.X757LeuextX33)	Argentina (Italian ancestors)	–	1	No	–	(75)
Exon 11 deletion	China	–	2	Yes	–	(93)
Exon 12 deletion	Quebec	–	6	Yes	–	(92)
Exon 12–13 duplication	Colombia	–	2	No	–	(94)
Exon 16 deletion	Finland	400–1075	14	Yes	Highly frequent among Finnish LS patients	(31, 32)
Exon 17–19 <i>MLH1</i> +exons 26–29 deletion <i>LRRFIP2</i> deletion	Portugal	~283	14	Yes	17% of LS mutation in their series	(38)

^aEstimation of the years that had passed since the most common ancestor appeared.

^bApparently unrelated families described in the referred paper.

effect in Newfoundland, where it presents in 27% of LS families (12).

The presence of a higher rate of founder mutations in a population can distort the generally accepted, distribution of mutations among the MMR genes [32% in *MLH1*, 38% in *MSH2*, 14% in *MSH6*, and 15% in *PMS2* (40)]. For example, the existence in a Spanish series, of two *MSH2* founder deletions (exon 4–8 and exon 7) doubles the rate of mutations in this gene compared to *MLH1* (41). Also, a substantial enrichment of Sardinians was seen among the patients carrying *MSH2* deletions

(or more precisely, exon 8 deletions) in an Italian series (10/13 exon 8 deletions) (42). Further investigations proved the founder effect of two exon 8 deletions, carried by 7 and 2 of the 10 families, respectively. Each deletion shared breakpoints and haplotype. Given the presence of these two founder mutations, 50% of LS Sardinian families carry a mutation in the *MSH2* gene (42). In the same vein, in the Netherlands more than half of all LS mutants are in *MSH6*. This is probably accounted for by the existence of two common founder mutations in this gene (c.467C>G and c.1614_1615delinsAG) (43).

Table 2. Founder mutations in *MSH2* gene and *EPCAM* gene

Mutation	Region/population	Estimated age (years) ^a	Families ^b	Haplotype	Features	Ref.
<i>MSH2</i>						
c.388_389del (p.Gln130fs)	Portugal	–	16	Yes	16% of LS mutations in their series	(37)
c.942+3A>T	Newfoundland	–	11	Yes	27% of LS mutations in their series	(12)
c.1165C>T (p.Arg389X)	Quebec	–	3	Yes	–	(92)
c.1452_1455del (p.Asn486fs)	China (Guangdong)	550–2575	10	Yes	21% of LS mutations in their series	(36)
c.1788_1790del (p.Asn596del)	Denmark	–	5	Yes	–	(95)
c.1906G>C (p.Ala636Pro)	Ashkenazi Jews	200–500	16	Yes	1/3 of Ashkenazy Jews with Amsterdam criteria	(51, 54)
c.2063T>G (p.Met688Arg)	Spain (Tenerife Island)	–	5	Yes	–	(79)
c.[2635-3T>C; 2635-5C>T]	Spain	–	4	Yes	–	(96)
Exon 1–6 deletion	North America	~500	41	Yes	6.8% of LS mutations in United States	(57, 58)
Exon 1–6 deletion	Italy	–	3	Yes	–	(60)
Exon 4–8 deletion	Spain	–	4	Yes	17% of LS mutations in their series	(41)
Exon 7 deletion	Spain	–	3	Yes	13% of LS mutations in their series	(41)
Exon 8 deletion	Italy (Sardinia Island)	–	7	Yes	–	(42)
Exon 8 deletion	Italy (Sardinia Island)	–	2	Yes	–	(42)
<i>EPCAM</i>						
Exon 8–9 deletion	Spain	–	3	Yes	–	(63)
Exon 8–9 deletion	Denmark	–	3	Yes	–	(62)

^aEstimation of the years that had passed since the most common ancestor appeared.

^bApparently unrelated families described in the referred paper.

Authors of this study also discussed whether the high frequency of *MSH6* mutations could be attributed to the use of less stringent clinical inclusion criteria than in other studies. They argued that the later age of onset of disease because of mutations in *MSH6* may lead to a persistence of founder mutations in this gene, as they had seen in their series (43).

A similar hypothesis has been proposed for *PMS2* gene by Tomsic et al. (44), who observed only 36 distinct mutations in a sample of 61 independently ascertained Caucasian probands of mixed European background with *PMS2* mutations. Six of these mutations were detected in more than two individuals and accounted for 51% of the ostensibly unrelated probands. By haplotyping they found that two mutations (c.137G>T and exon 10 deletion) were founders and a third one (c.1A>G) was a probable founder (44). They suggested that it is possible that the two MMR genes with the lowest penetrance (*PMS2* and *MSH6*) also share the property of having frequent recurrent or founder mutations, being maybe more abundant in *PMS2* (44). Although this is a plausible hypothesis, considering the founder mutations in the MMR genes that have been described so far (Tables 1–3), we do not notice an increased accumulation in *MSH6* and *PMS2* compared with *MLH1* and *MSH2*. This could be because of the fact that lower penetrance and higher age of onset of LS in *MSH6* and *PMS2* genes (45–47) may uncover the presence of mutations in these genes. Additionally,

MSH6 and *PMS2* were discovered to be associated to LS later than *MLH1* and *MSH2*, therefore the later establishment of their genetic testing, added to the difficulty to screen *PMS2* because of the presence of many pseudogenes, may be delaying as well the discovery of founder mutations. More studies will be needed to more precisely determine the distribution of founder mutations among the MMR genes.

Founder mutations in AJ

Mutation spectra and gene distribution among AJ are unique because of their particular genetic isolation. Therefore, founder mutations are commonly seen (48–52). In LS, three founder mutations have been showed to account for 73% of all MMR genes mutations in a cohort of AJ from Israel, thus changing again the distribution of mutations (75% in *MSH2*, 18% in *MSH6* and only 8% in *MLH1*) (53). The most common one appears in *MSH2* (c.1906G>C), is highly penetrant in the AJ population and dates 200–500 years ago (51, 54). The other two, present in *MSH6* gene (c.3959_3962del and c.3984_3987dup) and showed to be highly penetrant as well and harbour a higher risk to develop EC than CRC (52). They appeared approximately 1425 and 1325 years ago, respectively (52). In the Israeli cohort of AJ, three patients carried one of the founder mutations in both alleles and developed constitutional mismatch

Mismatch repair genes founder mutations in Lynch syndrome

Table 3. Founder mutations in *MSH6* gene and *PMS2* gene

Mutation	Region/population	Estimated age (years) ^a	Families ^b	Haplotype	Features	Ref.
<i>MSH6</i>						
c.10C>T (p.Gln4X)	Quebec	~513	11	Yes	Higher risk of EC than CRC	(97)
c.467C>G (p.Ser156X)	Netherlands	–	7	Yes	–	(43)
c.650dupT (p.Lys218X)	Netherlands	–	7	Yes	–	(98)
c.1346T>C (p.Leu449Pro)	Sweden	>300	5	No	Late onset age but high lifetime risk of LS tumors	(99)
c.1614_1615delinsAG (p.Tyr538X)	Netherlands	–	3	Yes	–	(43)
c.2931C>G (p.Trp977X)	Sweden	>200	2	No	Late onset age but high lifetime risk of LS tumors	(99)
c.2983G>T (p.Glu995X)	Finland	–	2	Yes	–	(100)
c.3959_3962del (p.Ala1320fs)	Ashkenazi Jews	~1425	8	Yes	–	(52)
c.3984_3987dup (p.Leu1330fs)	Ashkenazi Jews	~1325	14	Yes	–	(52)
c.137G>T (p.Ser46Ile)	US (Caucasian)	–	10	Yes	–	(44)
c.736_741delins11 (p.Pro246fs)	US (British, Swedish)	~1625	12	Yes	20% of <i>PMS2</i> mutation carriers, low penetrance	(56)
c.903G>T (p. Tyr268) (exon 8 skipping)	US (Caucasian)	–	3	Yes	–	(44)
c.989-1G>T	Norway	–	>2	No	–	(101, 102)
Exon 10 deletion	US (Caucasian)	–	5	Yes	–	(44)

^aEstimation of the years that had passed since the most common ancestor appeared.

^bApparently unrelated families described in the referred paper. [Correction added on 9 February 2015, after first online publication: The founder mutation “c.10C>T (p.Gln4X)” was previously omitted and this has now been added in Table 3 and as Reference 97. References after 97 have been pushed back by one place.]

repair deficiency (CMMR-D) (53). CMMR-D is caused by biallelic mutations in the MMR genes and leads to haematological malignancies and tumors of brain and bowel early in childhood (55). The existence of founder mutation can be associated with a higher prevalence of the deleterious allele in the population, which can result in unexpectedly frequent occurrence of biallelic mutations in some populations. Similarly, Clendenning et al. (56) underlined the significant prevalence of a founder *PMS2* mutation (c.736_741delins11), which appeared in 1 of 399 controls. Despite its reported reduced penetrance, over time, if the number of heterozygous carriers increases in the population, a rise in the number of homozygous carriers presenting with CMMR-D is expected (56).

Founder mutations in heterogeneous populations

Not all LS founder mutations are limited to specific, relatively isolated regions or communities; they also occur rarely in outbred populations. A remarkable example is the American founder mutation (AFM) in *MSH2* (exon 1–6 deletion), which was initially identified in nine families from the United States (57) and subsequently in 32 more (58). It was estimated that 6.8% of LS in the United States are because of the AFM (57), and was calculated to be carried by 18,981 (95%CI, 6038–34,466) Americans

(59). Nevertheless, recent estimates point a higher prevalence than previously thought, being clearly prominent in Ohio, Kentucky, and Texas states (58). A second *MSH2* exon 1–6 deletion, with different breakpoints and haplotype has been found to be shared by three families from northern Italy (60). Other founder mutations have been identified in the United States with a lower prevalence. In *MLH1* gene, a splicing mutation (c.589-2A>G) has been found in 10 unrelated American families on a large shared haplotype, representing 1% of LS mutations carriers diagnosed in the Mayo Clinic (61). The same mutation has also been described as a founder but in a different haplotype, in Italy (61). Several *PMS2* founder mutations have been described in the United States (44, 56).

Founder epimutations

Epimutations have been also described to cause LS by two different mechanisms. Germline deletions of the *EPCAM* gene cause that its transcription extends into the *MSH2* adjacent gene and subsequently, *MSH2* promoter, in *cis* with the deletion, is methylated and *MSH2* is therefore inactivated (62). Two founder mutations have been described so far in *EPCAM* gene, one in Denmark and the other in Spain (62, 63). Transmission of *MLH1* gene epimutations have also been reported to occur in

both non-Mendelian (64) and autosomal dominant patterns linked to localized *cis*-acting genetic variants (65, 66). Consistent with the latter, up to five families (two from Western Australia, two from the US and one from the Netherlands) have been showed to carry the same two mutations in *MLH1* (c.[−27C>A; c.85G>T]), which confer cancer susceptibility through its propensity for soma-wide epigenetic silencing (67). All families identified with such haplotype are of European ethnicity and in four of them, sharing of a common haplotype could be proven, providing strong evidences of a common ancestor with European origin (67). It is interesting that by individually comparing haplotypes from one of the Australian families with the two American and the Dutch ones, authors could show a larger haplotype was shared between the Australian and the US families, suggesting they are more closely related to one another than to the Dutch family (67).

Founder mutations and migratory patterns

Founder mutations in the United States

As shown by the latter example, the identification and characterization of MMR genes founder mutations in different and sometimes far-away geographical areas allows us to retrace the main migratory patterns that have involved large populations in the past centuries. Origins and prevalence of the AFM in *MSH2* gene (exon 1–6 deletion) have been thoroughly studied and discussed by Clendenning et al. (58). Although the mutation was previously thought to be carried by a putative common ancestor who migrated to the United States from Germany in the early 18th century, a time of significant European immigrations (68), the subsequent characterization of haplotypes flanking the mutation for 29 additional families suggested an earlier founding event, around 500 years ago. Twenty-seven of the AFM-carrier families could be linked into seven extended families (subfounder families), each with a common ancestor being born between 1700 and the early 1800s. Thus, Clendenning et al. proposed that either the subfounder families were in the United States before this period of time so the mutation was introduced by an early European immigrant or by a Native American, or the mutation originated in Europe but was carried to the US by several individuals during the greater European immigrations. The fact that no carriers have been found in Europe better supports the first hypothesis (58).

The other AFM, seen in *MLH1* gene in the United States (c.589-2A>G) also exemplifies how, by studying the haplotypes of founder mutation carriers, we can get anthropologically interesting theories (61). This splicing mutation appeared in 10 US and 3 Italian families. In the United States, it occurs in a large haplotype (~4.8 Mb) that also harbors a missense variant (c.2146G>A, p.V716M), with an approximate age of 450 years. In Italy, the mutation is shared in a shorter haplotype (~2.2 Mb) that does not carry the p.V716M missense variant. Interestingly, the p.V716M was found by itself in United States, Germany and Italy, in individuals with a common haplotype of 280 kb, which allowed

the estimation of its age (5600 years). Therefore authors suggested that the p.V716M represents a single, ancient mutational event, and that the splicing mutation arose at least twice, once in an early American immigrant (or in an ancestor of an immigrant) in a chromosome carrying the ancestral p.V716M, and once elsewhere (perhaps in Italy) a longer time ago (61).

Italian founder mutations

The case of Italian families is interesting, with several examples of their migratory activity within the LS founder mutations. In the early part of the 20th century, about four million people moved from Italy; half of these migrated to Northern Europe, whereas the great majority of the rest left to the US, Canada, and Australia (69). Specifically, the Italian colonization of the province of Quebec in Canada began in the mid-19th century. According to this, two different *MLH1* founder mutations were identified in unrelated families of Italian origin in Quebec (70). The c.1831delAT was described in two Italian-Quebec families sharing the same haplotype (70). The c.545+3A>G splicing mutation was found in the same haplotype in an Italian family from a town close to Naples (71) and in a Quebec family that originates from the region of Italy around Naples, which is consistent with most Italian Immigrants to North America coming from Southern Italy (70). This mutation has also appeared in three Brazilian families but no haplotype or genealogical study was done to link them to the Italian founder mutation (72, 73). Similarly, the *MLH1* c.2269dup has shown a founder effect in the northern Italian district of Modena and Reggio Emilia by haplotype evaluation (74) and has also been found in an Argentinean family whose ancestors were natives from the Reggio Emilia area (75) (Fig. 1).

Migratory flows within different regions of the same country

Other cases of MMR genes founder mutation well exemplify the big immigration waves from Europe to America (12, 44, 56), but other studies show that the current distribution of more local founder mutations can be explained by migratory patterns in geographically localized subsets of populations. Two examples are provided by Borras et al. by means of the ancestral study of two *MLH1* founder mutations in Spain (33). The splice variant c.306+5G>A was found in several families with ancestors coming from the Ebro river valley, in northern Spain. Its age was estimated to be ~1879 years. Taking into account the fact that the river valley is geographically isolated by mountain ranges, and the Ebro river was navigable until the 19th century, they hypothesize that the mutation arose somewhere in the valley and was distributed along the river over the years (33). The other founder mutation, c.1865T>A, was carried by families with ancestors in the mountainous province of Jaén, in Southern Spain and was proven to be of more recent origin (~384 years). This was consistent with the identified probands being mainly from Madrid and Barcelona, frequent destinations of internal migratory movements during the period of 1960–1970 (33).

Fig. 1. World map, showing the geographic ancestral origin and the supposed migration flows (arrows) of some of the main Italian *MLH1* and *MSH2* founder mutations. Different founder mutations are shown: *MLH1* founder mutations, shared by families living in the Naples and in Quebec; *MLH1* founder mutations carried by families living in the district of Modena and Argentina as well as by Italian and Brazilian families; *MLH1* founder mutation in USA (c.589-2A>G); Caucasian Australian c.-27C>A and c.85G>T *MLH1* founder mutations; AFM, exon 1–6 *MSH2* deletion; Finnish founder mutations c.1732-2243_1896+404del and c.454-1G>A.

In Hong Kong, 10 families have been shown to share an *MSH2* founder mutation c.1452_1455del in a common haplotype (36). Interestingly, they all originated from the Guangdong province of southern China, which is the origin of the most Hong Kong inhabitants. Given that during the 19th and 20th centuries there were major emigrations from Hong Kong and Guangdong province, this mutation is interesting not only for its founder effect in China, but also for Chinese communities worldwide (36).

Diagnostic, surveillance and management implications of LS founder mutations

It is well known that the presence of founder mutations in a specific geographical area or population can be very helpful in designing cost-effective molecular diagnostic approaches. By screening a particular frequent founder mutation as the first step in the routine screening for LS we can avoid further expensive mutational testing in a significant number of samples. The most evident case is probably found in Finland, where the screening of the two founder mutations that account for around half of their LS families is a first

step in the mutation analysis (76). In our experience in Northern Italy, when tumor IHC is suggestive for *MLH1* alterations, the germline mutation analysis starts from the *MLH1* founder mutation typically found in the area (c.2269dup) (74). Raskin et al. proposed that a panel designed to detect the known AJ founder mutations (*MSH2* c.1906G>C, *MSH6* c.3959_3962del and c.3984_3987dup, *APC* I1307K, and *BLM* Ash) could have value as a first-line screen in all AJ CRC and/or EC cases, irrespective of family history, IHC or MSI status (52). The benefit of founders becomes even more evident when the mutations are gross rearrangements. In most of these cases the exact breakpoints have been characterized, thus permitting the design of mutation detection by a simple cost and time-effective PCR test. In this line, it was proposed a test of this kind for the AFM, as a first line of molecular testing in patients whose tumors stain negatively for *MSH2* (58). A similar approach is used in Sardinia for the two founder *MSH2* exon 8 deletions, found to have different breakpoints (42). Pérez-Carbonero also suggested the need to design and implement as a pre-screening a simple, fast, and cheap method to detect their two founder mutations

in *MSH2* (exon 4–8 and exon 7 deletions) (41). The standardization of next generation sequencing (NGS) methods and analyses in the past few years is starting to make possible the introduction of this technology into the diagnostic molecular strategies, usually through the analysis of gene panels (77). Possibly, with the future global establishment of NGS in the genetic screening algorithms of LS, the existence of founder mutations will partially lose its diagnostic interest; the above mentioned technique has, in fact, shown promising results in the detection of all classes of MMR mutations, including single nucleotide variants, small insertions and deletions, and large copy number variants (78). However, those founder mutations with a high prevalence within specific populations can still represent a useful cost-effective tool before considering the more expensive NGS approaches.

A significant proportion of the mutations found in LS are missense or putative splice variants with unknown clinical significance. Although some algorithms to clarify their putative pathogenic effect have been proposed (30), in a typical routine diagnostic setting it is not affordable to address the effects of each of the variants encountered. When these changes appear to be founder in a certain population, more research efforts have been made to elucidate the effect of the variants thus improving genetic counseling of carrier families. Through segregation investigation, computational analyses, mRNA processing and stability assays and protein expression experiments, Borrás et al. were able to confirm that two *MLH1* founder changes from Spain, a splice variant (c.306+5G>A) and a missense variant (c.1865T>A), were pathogenic and the cause of the disease in carrier families (33). However, in most of the cases a less thorough characterization, without functional assays has been sufficient to show the causal deleterious effect of the founder variants. In Tenerife Island, the *MSH2* c.2063T>G missense variant was considered pathogenic because of the switch of polarity of the aminoacid change (p.Met688Arg) and the conservation between species of the affected residue, which belongs to an important functional domain of the protein (79). Apart from these examples, several other criteria and functional assays have been used to determinate the pathogenicity of the several variants presented in Tables 1–3.

In general, it is accepted that penetrance of cancer among *MLH1* and *MSH2* is higher than for *MSH6* and *PMS2* (47, 80) and that EC is more frequently found than CRC in women carrying *MSH6* mutations (81). Some founder mutations have been described to cause differential phenotypes. In Italy, the mutation c.2252_2253del significantly increased the risk of pancreatic tumors compared with other *MLH1* mutations (82). The two founder mutations described in *MLH1* gene by Borrás et al. (c.306+5G>A and c.1865T>A), showed a lower penetrance compared to other pathogenic Spanish *MLH1* mutations (33). In Denmark, the founder mutation c.1667+2_1667+8del7ins4 conferred comparable risks for CRC and lower risks for extracolonic cancer than the other *MLH1* mutant Danish families (35). In Northern Italy, a genotype–phenotype analysis of the

founder mutation c.2269dup revealed a proclivity to multiple tumors arising in the same subject and a higher tumor burden per family compared to other *MLH1* or *MSH2* mutations (83). However, most of the founder studies either do not thoroughly examine particular clinical characteristics in the carrier families, or the phenotypic patterns are similar to the expected. Therefore, although preliminary search for common founder mutations permits cost-effective and time-saving diagnostics strategies for LS, this cannot yet be translated into tailored cancer control strategies because of the lack of evidences of highly specific phenotypes related to the presence of founder mutations.

Conclusions

The identification of at least 55 founder mutations in LS has helped the diagnostic, surveillance and management of LS patients for almost two decades. In some populations, founder mutations represent up to 50% of their LS-causing mutations, which is extremely helpful for the development of cost-effective strategies to diagnose LS. This becomes even more advantageous in the case of founder gross rearrangements thanks to the possibility of designing easy polymerase chain reaction (PCR) assays to detect them once the breakpoints are known. With the imminent introduction of NGS into the molecular diagnostic algorithms of LS, pre-screening of the highly prevalent founder mutations will help reduce the number of samples undergoing expensive high-throughput sequencing. Although several studies have assessed the phenotypical features of LS founder mutations, no clinical management strategies specific for founder mutations seem to be necessary.

Acknowledgements

We wish to thank Dr Annamaria Pollio (Department of Neurosciences, University of Padua) for critical review of the manuscript. We are also grateful to Prof. Giovanni Pellacani, Dr Monia Maccaferri (Division of Dermatology, University of Modena and Reggio Emilia) and Dr Lorenza Pastorino (University of Genoa) for their helpful suggestions. We would like to thank Dr William Foulkes for the thorough revision of the manuscript. E. C. is a recipient of a Marie Curie International Outgoing Fellowship (PIOF-GA-2012-327193), co-sponsored with the Catalan Institute of Oncology-Bellvitge Institute for Biomedical Research, Barcelona, Spain.

References

1. Boland CR, Lynch HT. The history of Lynch syndrome. *Fam Cancer* 2013; 12: 145–157.
2. Lynch HT, Lynch PM. Foreword for "100 years of Lynch syndrome". *Fam Cancer* 2013; 12: 143–144.
3. Lynch HT, Lynch PM, Lanspa SJ et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. *Clin Genet* 2009; 76: 1–18.
4. Fishel R, Lescoe MK, Rao MR et al. The human mutator gene homolog *MSH2* and its association with hereditary nonpolyposis colon cancer. *Cell* 1993; 75: 1027–1038.
5. Miyaki M, Konishi M, Tanaka K et al. Germline mutation of *MSH6* as the cause of hereditary nonpolyposis colorectal cancer. *Nat Genet* 1997; 17: 271–272.

6. Nicolaides NC, Papadopoulos N, Liu B et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. *Nature* 1994; 371: 75–80.
7. Papadopoulos N, Nicolaides NC, Wei YF et al. Mutation of a mutL homolog in hereditary colon cancer. *Science* 1994; 263: 1625–1629.
8. Peltomäki P. Epigenetic mechanisms in the pathogenesis of Lynch syndrome. *Clin Genet* 2014; 85: 403–412.
9. Gruber SB. New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. *Gastroenterology* 2006; 130: 577–587.
10. Vasen HF, Blanco I, Aktan-Collan K et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut* 2013; 62: 812–823.
11. Fokkema IF, Taschner PE, Schaafsma GC et al. LOVD v.2.0: the next generation in gene variant databases. *Hum Mutat* 2011; 32: 557–563.
12. Froggatt NJ, Green J, Brassett C et al. A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. *J Med Genet* 1999; 36: 97–102.
13. Froggatt NJ, Joyce JA, Davies R et al. A frequent hMSH2 mutation in hereditary non-polyposis colon cancer syndrome. *Lancet* 1995; 345: 727.
14. Guo SW, Xiong M. Estimating the age of mutant disease alleles based on linkage disequilibrium. *Hum Hered* 1997; 47: 315–337.
15. Kimura M, Ohta T. The age of a neutral mutant persisting in a finite population. *Genetics* 1973; 75: 199–212.
16. McPeck MS, Strahs A. Assessment of linkage disequilibrium by the decay of haplotype sharing, with application to fine-scale genetic mapping. *Am J Hum Genet* 1999; 65: 858–875.
17. Rannala B, Bertorelle G. Using linked markers to infer the age of a mutation. *Hum Mutat* 2001; 18: 87–100.
18. Rannala B, Reeve JP. High-resolution multipoint linkage-disequilibrium mapping in the context of a human genome sequence. *Am J Hum Genet* 2001; 69: 159–178.
19. Reeve JP, Rannala B, DMLE+: Bayesian linkage disequilibrium gene mapping. *Bioinformatics* 2002; 18: 894–895.
20. Slatkin M, Rannala B. Estimating the age of alleles by use of intraallelic variability. *Am J Hum Genet* 1997; 60: 447–458.
21. Slatkin M, Rannala B. Estimating allele age. *Annu Rev Genomics Hum Genet* 2000; 1: 225–249.
22. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. *Am J Epidemiol* 2000; 151: 839–845.
23. Behar DM, Metspalu E, Kivisild T et al. The matrilineal ancestry of Ashkenazi Jewry: portrait of a recent founder event. *Am J Hum Genet* 2006; 78: 487–497.
24. Olsson KS, Ritter B, Raha-Chowdhury R. HLA-A3-B14 and the origin of the haemochromatosis C282Y mutation: founder effects and recombination events during 12 generations in a Scandinavian family with major iron overload. *Eur J Haematol* 2010; 84: 145–153.
25. Lopez-Escribano H, Parera MM, Guix P et al. Balearic archipelago: three islands, three beta-thalassemia population patterns. *Clin Genet* 2013; 83: 175–180.
26. Morral N, Bertranpetit J, Estivill X et al. The origin of the major cystic fibrosis mutation (delta F508) in European populations. *Nat Genet* 1994; 7: 169–175.
27. Tamura D, DiGiovanna JJ, Kraemer KH. Founder mutations in xeroderma pigmentosum. *J Invest Dermatol* 2010; 130: 1491–1493.
28. Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. *Biomed Res Int* 2013; 2013: 928562.
29. Lang J, Hayward N, Goldgar D et al. The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry. *Genes Chromosomes Cancer* 2007; 46: 277–287.
30. Pineda M, Gonzalez S, Lazaro C et al. Detection of genetic alterations in hereditary colorectal cancer screening. *Mutat Res* 2010; 693: 19–31.
31. Moisio AL, Sistonen P, Weissensbach J et al. Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer. *Am J Hum Genet* 1996; 59: 1243–1251.
32. Nystrom-Lahti M, Kristo P, Nicolaides NC et al. Founding mutations and Alu-mediated recombination in hereditary colon cancer. *Nat Med* 1995; 1: 1203–1206.
33. Borras E, Pineda M, Blanco I et al. MLH1 founder mutations with moderate penetrance in Spanish Lynch syndrome families. *Cancer Res* 2010; 70: 7379–7391.
34. Jager AC, Bisgaard ML, Myrholm T et al. Reduced frequency of extra-colonic cancers in hereditary nonpolyposis colorectal cancer families with monoallelic hMLH1 expression. *Am J Hum Genet* 1997; 61: 129–138.
35. Therkildsen C, Isinger-Ekstrand A, Ladelund S et al. Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation. *Fam Cancer* 2012; 11: 579–585.
36. Chan TL, Chan YW, Ho JW et al. MSH2 c.1452-1455delAATG is a founder mutation and an important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese population. *Am J Hum Genet* 2004; 74: 1035–1042.
37. Pinheiro M, Pinto C, Peixoto A et al. The MSH2 c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families. *Clin Genet* 2013; 84: 244–250.
38. Pinheiro M, Pinto C, Peixoto A et al. A novel exonic rearrangement affecting MLH1 and the contiguous LRRFIP2 is a founder mutation in Portuguese Lynch syndrome families. *Genet Med* 2011; 13: 895–902.
39. Desai DC, Lockman JC, Chadwick RB et al. Recurrent germline mutation in MSH2 arises frequently de novo. *J Med Genet* 2000; 37: 646–652.
40. Palomaki GE, McClain MR, Melillo S et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med* 2009; 11: 42–65.
41. Perez-Cabornero L, Borras Flores E, Infante Sanz M et al. Characterization of new founder Alu-mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype. *Cancer Prev Res (Phila)* 2011; 4: 1546–1555.
42. Borelli I, Barberis MA, Spina F et al. A unique MSH2 exon 8 deletion accounts for a major portion of all mismatch repair gene mutations in Lynch syndrome families of Sardinian origin. *Eur J Hum Genet* 2013; 21: 154–161.
43. Ramsoekh D, Wagner A, van Leerdam ME et al. A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. *Gut* 2008; 57: 1539–1544.
44. Tomsic J, Senter L, Liyanarachchi S et al. Recurrent and founder mutations in the PMS2 gene. *Clin Genet* 2013; 83: 238–243.
45. Hendriks YM, Wagner A, Morreau H et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. *Gastroenterology* 2004; 127: 17–25.
46. Plaschke J, Engel C, Kruger S et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. *J Clin Oncol* 2004; 22: 4486–4494.
47. Senter L, Clendenning M, Sotamaa K et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology* 2002; 135: 419–428.
48. Gruber SB, Ellis NA, Scott KK et al. BLM heterozygosity and the risk of colorectal cancer. *Science* 2002; 297: 2013.
49. Niell BL, Long JC, Rennett G et al. Genetic anthropology of the colorectal cancer-susceptibility allele APC I1307K: evidence of genetic drift within the Ashkenazim. *Am J Hum Genet* 2003; 73: 1250–1260.
50. Shiri-Sverdlov R, Oefner P, Green L et al. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. *Hum Mutat* 2000; 16: 491–501.
51. Foulkes WD, Thiffault I, Gruber SB et al. The founder mutation MSH2*1906G→C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. *Am J Hum Genet* 2002; 71: 1395–1412.
52. Raskin L, Schwenter F, Freytsis M et al. Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome. *Clin Genet* 2011; 79: 512–522.
53. Goldberg Y, Kedar I, Kariiv R et al. Lynch Syndrome in high risk Ashkenazi Jews in Israel. *Fam Cancer* 2014; 13: 65–73.
54. Sun S, Greenwood CM, Thiffault I et al. The HNPCC associated MSH2*1906G→C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population. *J Med Genet* 2005; 42: 766–768.
55. Wimmer K, Kratz CP. Constitutional mismatch repair-deficiency syndrome. *Haematologica* 2010; 95: 699–701.
56. Clendenning M, Senter L, Hampel H et al. A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome. *J Med Genet* 2008; 45: 340–345.
57. Wagner A, Barrows A, Wijnen JT et al. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation

- detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. *Am J Hum Genet* 2003; 72: 1088–1100.
58. Clendenning M, Baze ME, Sun S et al. Origins and prevalence of the American Founder Mutation of MSH2. *Cancer Res* 2008; 68: 2145–2153.
 59. Lynch HT, de la Chapelle A, Hampel H et al. American founder mutation for Lynch syndrome. Prevalence estimates and implications. *Cancer* 2006; 106: 448–452.
 60. Stella A, Surdo NC, Lastella P et al. Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC. *Clin Genet* 2007; 71: 130–139.
 61. Tomsic J, Liyanarachchi S, Hampel H et al. An American founder mutation in MLH1. *Int J Cancer* 2012; 130: 2088–2095.
 62. Ligtenberg MJ, Kuiper RP, Chan TL et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. *Nat Genet* 2009; 41: 112–117.
 63. Mur P, Pineda M, Romero A et al. Identification of a founder EPCAM deletion in Spanish Lynch syndrome families. *Clin Genet* 2014; 85: 260–266.
 64. Hitchins MP, Wong JJ, Suthers G et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. *N Engl J Med* 2007; 356: 697–705.
 65. Hitchins MP, Rapkins RW, Kwok CT et al. Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5'UTR. *Cancer Cell* 2011; 20: 200–213.
 66. Morak M, Koehler U, Schackert HK et al. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. *J Med Genet* 2011; 48: 513–519.
 67. Kwok CT, Vogelaar IP, van Zelst-Stams WA et al. The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. *Eur J Hum Genet* 2014; 22: 617–624.
 68. Lynch HT, Coroneo SM, Okimoto R et al. A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. *JAMA* 2004; 291: 718–724.
 69. Cavalli-Sforza LL, Menozzi P, Piazza A. The history and geography of human genes. Princeton, NJ: Princeton University Press, 1994.
 70. Thiffault I, Foulkes WD, Marcus VA et al. Putative common origin of two MLH1 mutations in Italian-Quebec hereditary non-polyposis colorectal cancer families. *Clin Genet* 2004; 66: 137–143.
 71. Pensotti V, Radice P, Prescittini S et al. Mean age of tumor onset in hereditary nonpolyposis colorectal cancer (HNPCC) families correlates with the presence of mutations in DNA mismatch repair genes. *Genes Chromosomes Cancer* 1997; 19: 135–142.
 72. Dominguez-Valentin M, Nilbert M, Wernhoff P et al. Mutation spectrum in South American Lynch syndrome families. *Hered Cancer Clin Pract* 2013; 11: 18.
 73. Valentin MD, da Silva FC, dos Santos EM et al. Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals. *Fam Cancer* 2011; 10: 641–647.
 74. Caluseriu O, Di Gregorio C, Lucci-Cordisco E et al. A founder MLH1 mutation in families from the districts of Modena and Reggio-Emilia in northern Italy with hereditary non-polyposis colorectal cancer associated with protein elongation and instability. *J Med Genet* 2004; 41: e34.
 75. Gomez L, Adi J, Ibarra J et al. Detection of a founder mutation in an Argentine family with hereditary non polyposis colorectal cancer. *Medicina (B Aires)* 2010; 70: 31–36.
 76. Salovaara R, Loukola A, Kristo P et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. *J Clin Oncol* 2000; 18: 2193–2200.
 77. Lohmann K, Klein C. Next generation sequencing and the future of genetic diagnosis. *Neurotherapeutics* 2014; 11 (4): 699–707.
 78. Pritchard CC, Smith C, Salipante SJ et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massive parallel sequencing. *J Mol Diagn* 2012; 14: 357–366.
 79. Medina-Arana V, Barrios Y, Fernandez-Peralta A et al. New founding mutation in MSH2 associated with hereditary nonpolyposis colorectal cancer syndrome on the Island of Tenerife. *Cancer Lett* 2006; 244: 268–273.
 80. Jenkins MA, Baglietto L, Dowty JG et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. *Clin Gastroenterol Hepatol* 2006; 4: 489–498.
 81. Baglietto L, Lindor NM, Dowty JG et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. *J Natl Cancer Inst* 2010; 102: 193–201.
 82. Borelli I, Casalis Cavalchini GC, Del Peschio S et al. A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns. *Fam Cancer* 2014; 13 (3): 401–413.
 83. de Leon MP, Benatti P, Di Gregorio C et al. Genotype-phenotype correlations in individuals with a founder mutation in the MLH1 gene and hereditary non-polyposis colorectal cancer. *Scand J Gastroenterol* 2007; 42: 746–753.
 84. van Riel E, Ausems MG, Hogervorst FB et al. A novel pathogenic MLH1 missense mutation, c.112A>C, p.Asn38His, in six families with Lynch syndrome. *Hered Cancer Clin Pract* 2010; 8: 7.
 85. Hiljadnikova-Bajro M, Josifovski T, Panovski M et al. A novel germline MLH1 mutation causing Lynch Syndrome in patients from the Republic of Macedonia. *Croat Med J* 2012; 53: 496–501.
 86. Lastella P, Patruno M, Forte G et al. Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation. *Fam Cancer* 2011; 10: 285–295.
 87. Tang R, Hsiung C, Wang JY et al. Germ line MLH1 and MSH2 mutations in Taiwanese Lynch syndrome families: characterization of a founder genomic mutation in the MLH1 gene. *Clin Genet* 2009; 75: 334–345.
 88. Stella A, Wagner A, Shito K et al. A nonsense mutation in MLH1 causes exon skipping in three unrelated HNPCC families. *Cancer Res* 2001; 61: 7020–7024.
 89. Mangold E, Pagenstecher C, Friedl W et al. Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer. *Int J Cancer* 2005; 116: 692–702.
 90. Shin YK, Heo SC, Shin JH et al. Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non-polyposis colorectal cancer families. *Hum Mutat* 2004; 24: 351.
 91. Hutter P, Couturier A, Scott RJ et al. Complex genetic predisposition to cancer in an extended HNPCC family with an ancestral hMLH1 mutation. *J Med Genet* 1996; 33: 636–640.
 92. Chong G, Jarry J, Marcus V et al. High frequency of exon deletions and putative founder effects in French Canadian Lynch syndrome families. *Hum Mutat* 2009; 30: E797–E812.
 93. Chan TL, Yuen ST, Ho JW et al. A novel germline 1.8-kb deletion of hMLH1 mimicking alternative splicing: a founder mutation in the Chinese population. *Oncogene* 2001; 20: 2976–2981.
 94. Alonso-Espinaco V, Giraldez MD, Trujillo C et al. Novel MLH1 duplication identified in Colombian families with Lynch syndrome. *Genet Med* 2011; 13: 155–160.
 95. Ripa RS, Katballe N, Wikman FP et al. Presymptomatic diagnosis using a deletion of a single codon in families with hereditary non-polyposis colorectal cancer. *Mutat Res* 2005; 570: 89–96.
 96. Menendez M, Castellvi-Bel S, Pineda M et al. Founder effect of a pathogenic MSH2 mutation identified in Spanish families with Lynch syndrome. *Clin Genet* 2010; 78: 186–190.
 97. Castellsague E, Liu J, Volenik A et al. Characterization of a novel founder MSH6 mutation causing Lynch syndrome in the French Canadian population. *Clin Genet* 2014.
 98. Berends MJ, Wu Y, Sijmons RH et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. *Am J Hum Genet* 2002; 70: 26–37.
 99. Cederquist K, Emanuelsson M, Wiklund F et al. Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome. *Clin Genet* 2005; 68: 533–541.
 100. Vahteristo P, Ojala S, Tamminen A et al. No MSH6 germline mutations in breast cancer families with colorectal and/or endometrial cancer. *J Med Genet* 2005; 42: e22.
 101. Grindedal EM, Aarset H, Bjornevoll I et al. The Norwegian PMS2 founder mutation c.989-1G>T shows high penetrance of microsatellite unstable cancers with normal immunohistochemistry. *Hered Cancer Clin Pract* 2014; 12: 12.
 102. Sijrsen W, Bjornevoll I, Engebretsen LF et al. A homozygote splice site PMS2 mutation as cause of Turcot syndrome gives rise to two different abnormal transcripts. *Fam Cancer* 2009; 8: 179–186.